Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis
2023年10月18日 - 2:54PM
Dow Jones News
By Giulia Petroni
Roche said that its Elecsys IL-6 test was approved in countries
carrying the "CE" safety mark to help diagnose neonatal sepsis, one
of the leading causes of death in newborns.
Neonatal sepsis is an infection involving the bloodstream within
the first four weeks of life, and can rapidly progress to
multisystem organ failure. An early diagnosis can potentially
decrease mortality rates and mitigate long-term consequences, the
Swiss pharmaceutical giant said Wednesday.
Elecsys IL-6, which is used to identify severe inflammatory
responses in patients, takes 18 minutes to run and only a small
amount of blood, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
October 18, 2023 01:39 ET (05:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 11 2024 まで 12 2024
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Roche Holdings Ltd AG (QX) (その他OTC): 0 recent articles
その他のRoche Holdings Ltd AG (QX)ニュース記事